- Home
- EKSO vs KPRX Comparison
EKSO vs KPRX Comparison
Compare EKSO & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EKSO | KPRX |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 7.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EKSO | KPRX |
|---|---|---|
| Price | $5.51 | $1.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $7.75 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 326.9K | 34.1K |
| Earning Date | 10-28-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,749,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $54.65 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.73 | $1.77 |
| 52 Week High | $14.97 | $4.18 |
Technical Indicators
Market Signals| Indicator | EKSO | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 65.38 | 37.27 |
| Support Level | $4.56 | $2.03 |
| Resistance Level | $5.09 | $2.23 |
| Average True Range (ATR) | 0.31 | 0.10 |
| MACD | 0.11 | -0.00 |
| Stochastic Oscillator | 92.68 | 2.94 |
Price Performance
Historical ComparisonAbout EKSO Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.